Rua signed an agreement with Portugal-based Cannprisma to conduct pre-commercial trials of Rua's cannabis varieties.
Following this agreement, Rua will send cannabis clones to Portugal.
The agreement is laid out in two stages: the crucial first stage is pre-commercial cultivation trials in Portugal to prove the performance of the varieties in the new environment. Following successful trials, the agreement allows for commercial production.
"This partnership underscores Rua's commitment to our strategy of cultivating our genetics at scale in export markets," said Rua CEO Paul Naske.
"Portugal is an efficient and well-established cultivation and manufacturing hub for cannabis products. Cannprisma has a proven track record in the development, cultivation, and export of high-quality medicinal cannabis."
"By conducting trials in collaboration with Cannprisma, we anticipate generating important data to scale our unique genetics for commercial production for sales in the key markets of Germany and the UK."
Rua began selling products in Germany in May 2023 in collaboration with distribution partner Nimbus Health. In December, Rua signed a distribution agreement with Target Health to supply Rua products in the growing UK market.
For more information:
Rua Bioscience
info@ruabio.com
ruabio.com